There is a particular kind of market study that costs a great deal and changes nothing. It is thorough, well-presented, and arrives three weeks after the board has already agreed, in principle, to proceed. Its findings are read as confirmation. Its caveats are read as caution to be managed. Nobody is being dishonest; the sequence simply guarantees the outcome.
The tell is never in the findings. It is in the scope.
Scope reveals the question that is actually being asked
Read the terms of reference for any commissioned market assessment and you can usually determine, in a paragraph or two, whether the decision is still open.
A genuinely open question sounds like: should we enter this market, and if so, in what structure and on what timeline? A settled question sounds like: size the opportunity in this market and identify the risks to our entry. The second formulation has already conceded the point. It asks for magnitude and mitigation, not for a verdict. Every subsequent hour of work is spent inside an assumption nobody has tested.
This matters more than it appears. An assessment scoped to find risks will find risks, and they will be presented as manageable, because that is what the framing invites. An assessment scoped to reach a verdict has to argue itself into or out of a position, and the argument is where the value is.
The three questions worth paying for
If you are commissioning this work, the scope should force answers to three things that organizations consistently get wrong.
What is the second-year operating cost, not the entry cost? Entry economics are usually modelled well. The cost of running a subsidiary once the launch team has gone home — local finance, compliance, a country manager who is not a founder, the tax and transfer-pricing overhead — is routinely underweighted by a wide margin. Firms do not usually fail at entry. They fail eighteen months later, when the market turns out to be real but the operating model is not.
Who specifically loses if you succeed, and what can they do about it? Competitive analysis that describes the landscape is nearly useless. Competitive analysis that names the two incumbents with both the motive and the means to respond, and states what their response would cost you, is worth the entire engagement. In concentrated markets, and particularly in regulated ones, the relevant competitive risk is rarely a better product. It is a distribution agreement you cannot access or a regulatory posture you cannot match.
What evidence would change our mind? This is the question that separates an assessment from a ratification. If the answer is nothing we are likely to find, the study should not be commissioned. The money is better spent on the entry itself, and the organization should at least be honest that it is making a judgement call rather than an evidence-based decision. There is nothing wrong with a judgement call. There is something wrong with paying six figures to dress one up.
Independence is a commercial arrangement, not a disposition
Advisors are not more honest than anyone else. They respond to incentives like everyone else. The reason to separate assessment work from implementation work is not that assessors are more virtuous — it is that an advisor who will be paid to execute the entry has a material interest in the entry proceeding.
This is manageable, but it must be managed explicitly. Either the assessment is bought from a party with no position in the outcome, or the engagement is structured so that a recommendation not to proceed is compensated identically to a recommendation to proceed. Firms that will not accept the second arrangement are telling you something useful.
The uncomfortable version
The most valuable market assessments we have delivered concluded that the client should not enter, or should not enter yet, or should enter through a partner rather than directly. Those engagements were not enjoyable. They were, in every case, cheaper than the alternative by an order of magnitude.
An assessment that cannot return a negative answer is not an assessment. It is a document. Organizations that have made this distinction internally — that have decided, before commissioning anything, what they would do with a negative finding — get materially better returns on the same spend.
Decide what would change your mind. Then commission the work that could find it.